April 12, 2019 | Industry Insights

Phacilitate 2019 Event Recap

Phacilitate is the world’s largest advanced therapies partnering event, bringing together experts and solution providers from all over the world to create the perfect opportunity to network, learn, and be inspired. Brian Hampson, Vice President of Hitachi Chemical Advanced Therapeutics Solutions, had this to say about the Phacilitate 2019 event:

Having been involved in cell therapy before it was even called that, it is incredibly exciting to now see commercialized cell and gene therapies that are literally saving lives and witness the rapid global growth of the industry. From the few hundred participants when I first attended Phacilitate a decade ago to over 1,600 this year, the conference continues to provide a valuable and eclectic mix of coverage including science, technology, clinical, regulatory, manufacturing, business, etc.

Download Phacilitate Post Show Report

Phacilitate continues to provide invaluable insights into the cell and gene therapy industry. Some of the major takeaways from Phacilitate are outlined below:

Key Takeaways from the Conference

  • The cost-effectiveness of manufacturing and delivering advanced therapeutic products are crucial for long-term success.
  • Collaboration across the advanced therapies industry is a necessity to overcome the industry’s major challenges and accelerate the application of cell and gene therapies.
  • Automation is essential to drive the success of the industry.
You can download the full post-show report from the Phacilitate event website.
*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH are all now operating under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

Stay up to date on the latest cell therapy industry insights

Related Articles

May 12, 2016

Reducing Idle Capacity Through the Factory of the Future

The following is an excerpt from an article published in the April issue of BioProcess international, entitled “Factories of the Future: Can Patient-Specific Cell Therapies Get there from ...

Read More
August 22, 2019

Moving Towards Automated Manufacturing for Cell Therapies

As more cell therapy products reach the “finish line” of U.S. Food and Drug Administration (FDA) approval and new regenerative medicine products begin the clinical development process, the ...

Read More
February 21, 2019

Bloomberg Law Article: Breakthrough Cancer Therapy Stalls in Manufacturing Bottleneck

In a recent Bloomberg Law article, Robert Preti, PhD, discusses how manufacturing bottlenecks are holding up cancer treatments from going to market. There has been a lot of success in the ...

Read More